Canagliflozin Mediates Effective Blockade of the mTORC1 - HIF-1a Pathway, Inhibits Growth and Enhances Non-Small Cell Lung Cancer (NSCLC) Response to Radiotherapy (RT)
- Resource Type
- Source
- International Journal of Radiation Oncology*Biology*Physics. 108:S56
- Subject
Canagliflozin Cancer Research Radiation business.industry medicine.medical_treatment non-small cell lung cancer (NSCLC) mTORC1 medicine.disease Blockade Radiation therapy Oncology medicine Cancer research Radiology, Nuclear Medicine and imaging business medicine.drug - Language
- ISSN
- 0360-3016